GlassScriptPhysician profile
Randy P Gordon
NPI 1487705711
$2,545.17
in general payments reported to CMS, 2019-2025
28 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,085 · 2022: $574 · 2023: $349 · 2024: $400 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.57 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $265.16 | 2021-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $216.71 | 2021-2024 | Airsupra, Farxiga |
| Abbvie INC. | $209.97 | 2021-2023 | |
| Lilly USA, LLC | $205.30 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $200.43 | 2022-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $159.53 | 2021 | |
| Abbott Laboratories | $158.62 | 2021-2024 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $122.51 | 2021-2023 | Trintellix |
| Amgen INC. | $116.27 | 2021 | |
| Janssen Pharmaceuticals, INC | $73.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $68.91 | 2021-2023 | Belsomra, Steglujan, Segluromet |
| Biohaven Pharmaceutical Holding Company LTD. | $65.21 | 2022 | |
| Amarin Pharma, INC. | $64.05 | 2021-2022 | |
| Antares Pharma, INC. | $39.44 | 2021-2024 | Xyosted |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35.19 | 2022-2025 | |
| Scilex Pharmaceuticals INC. | $33.76 | 2021 | |
| Glaxosmithkline, LLC. | $31.04 | 2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $29.88 | 2021 | |
| Sunovion Pharmaceuticals INC. | $29.80 | 2021 | |
| Edwards Lifesciences Corporation | $22.14 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.95 | 2023 | |
| Astellas Pharma US INC | $13.73 | 2021 | |
| Exact Sciences Corporation | $13.61 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.70 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.95 | 2021 | |
| Biogen, INC. | $11.59 | 2021 | |
| Genentech USA, INC. | $10.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.